For years, Cell Therapeutics CEO Jim Bianco has boasted about the company's long-standing relationship with Novartis. But as of this morning, the relationship is history. The Seattle-based biotech says that it has reacquired the rights Novartis ($NVS) gained on Pixuvri (pixantrone) and Opaxio. The biotech ($CTIC) has agreed to pay out certain milestones on the programs. The company's shares are up 9% this morning. Release